ApprovalTrail

Drug · DIN 02530325

COMIRNATY

MAROON CAP VIAL (6 MONTHS TO <5 YEARS) AFTER DILUTION CONTAINS 10 DOSES OF 0.2 ML

No: no longer authorized

The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.

Status Cancelled Post Market since May 3, 2024; first marketed September 15, 2022.
Drug Identification Number (DIN)
02530325
Company (DIN owner)
Biontech Manufacturing GmbhMainz, Rheinland-Pfalz, Germany
Schedule
Schedule d
Dosage form
Suspension
Route
Intramuscular
Therapeutic class (ATC)
Covid-19, rna-based vaccine J07BN01
Class
Human
Record last updated
August 29, 2025

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
TOZINAMERAN3 MCG0.2 ML

Notices of Compliance

Health Canada approvals that name this DIN.

  • September 9, 2022: NOC 28915Supplement to a New Drug Submission (SNDS) · Extension of indication: Comirnaty (COVID-19 Vaccine, mRNA) is indicated for active immunization to prevent coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) in individuals 6 months of age and older

Recalls and safety alerts that mention it

Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “comirnaty”. A notice may cover another product or only some lots: read it to see what it covers.

Other DINs named COMIRNATY